Ad hoc-Mitteilungen
• 16.04.21 Frontline • 16.04.21 SNP • 16.04.21 Steinhoff International Holdings • 16.04.21 Takkt • 16.04.21 HBM Healthcare Investments • 16.04.21 Ageas • 16.04.21 Suominen • 16.04.21 Klaipedos Nafta • 16.04.21 Sampo • 16.04.21 TEMPTON PERS FLB 19/23 •
  • Startseite
  • Aktien
  • Sanofi-Aventis ADR
  • News
  • aktualisieren
  • Specials: Webinare

    • Sanofi-Aventis ADR News

    42,50 € 0,00% +0,00 €
    11:05:18 Uhr L&S RT | Mehr Kurse »
    WKN: 662283
    ISIN: US80105N1054
    US-Symbol: SNY
    Typ: Aktie
    Jetzt für 0€ handeln

    Sanofi-Aventis ADR News

      
    < Zurück < Zurück
    von 22
    Weiter > Weiter >
    < Zurück < Zurück
    von 22
    Weiter > Weiter >
    07.04.21 - PR Newswire
    Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
    Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines * Launch of a new and more impactful global ...
    31.03.21 - PR Newswire
    FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    FDA approves Sarclisa® (isatuximab-​irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma - Sarclisa regimen ...
    12.01.21 - PR Newswire
    Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
    Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor Biond to receive $125 million ...
    21.10.20 - PR Newswire
    Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease
    Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease * $1 million in research ...
    12.09.20 - PR Newswire
    (PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?
    (PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price? PR Newswire
    09.09.20 - PR Newswire
    Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020
    Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020 - New data on investigational brain-...
    17.08.20 - PR Newswire
    (PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?
    (PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price? PR Newswire
    17.08.20 - PR Newswire
    Sanofi to acquire Principia Biopharma
    Sanofi to acquire Principia Biopharma * Further strengthens core R&D areas of autoimmune and allergic diseases * Provides full control of brain-​penetrant BTK inhibitor ...
    29.07.20 - PR Newswire
    Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
    Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation PR Newswire
    14.07.20 - PR Newswire
    Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development
    Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development * New alliance will use insights from translational and clinical ...
    09.07.20 - PR Newswire
    Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients
    Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients - Kymera to receive $150 million upfront with more ...
    19.06.20 - PR Newswire
    FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
    FDA approves new Dupixent® (dupilumab) pre-​filled pen designed to support more convenient self-​administration * Single-​dose (300 mg) pre-​filled pen provides additional ...
    15.06.20 - PR Newswire
    Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II
    Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II - Preclinical data show anti-​tumor activity in Sanofi's investigational compounds, including ...
    14.06.20 - PR Newswire
    Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program
    Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program * Additional donation of factor therapy fulfills 2014 pledge to donate up ...
    25.05.20 - PR Newswire
    Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
    Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase PR Newswire
    13.05.20 - PR Newswire
    Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program
    Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program - Emerging data demonstrate commitment to advancing cancer care, ...
    24.04.20 - PR Newswire
    Sanofi at forefront of fight against COVID-19 in Q1 2020
    Sanofi at forefront of fight against COVID-19 in Q1 2020 PR Newswire
    12.04.20 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY PR Newswire
    12.04.20 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY PR Newswire
    16.03.20 - PR Newswire
    Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19
    Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19 * U.S. Phase 2/3 trial initiated and will begin enrolling patients ...
    < Zurück < Zurück
    von 22
    Weiter > Weiter >

    Newssuche

      

    Videos

      
    16.04.21 0,00%
    Most Actives - die meistgehandelten Aktien des Tages: Curevac, Daimler und BASF
    Viola Grebe blickt auf die meistgehandelten Werte beim Onlinebroker Flatex. Welche Aktien werden aktuell ... Mehr »

    Webinare im April

      
    16.04.2021, 12:00 Uhr
    Nachmittags-Trading mit Dax, Dow und Devisen
    17.04.2021, 08:00 Uhr
    9. Börsentag kompakt ONLINE
    19.04.2021, 06:25 Uhr
    99 % Trefferquote zur Markteröffnung
    Alle Webinare